← Back to Home

Giving Cancer-Fighting Immune Cells Backup: USC Builds an Expandable Manufacturing Platform Using Progenitor Cells

Starting with immature immune cells, researchers established a source that can replenish cancer-fighting cells in mice. This approach could improve the manufacturing and sustained activity of cell therapies, but safety and efficacy challenges remain before it can be used in humans.

By SURL BioNews

Engineering immune cells to fight cancer involves more than enabling them to recognize tumors. It also requires producing enough cells and ensuring that they persist after entering the body. A team led by the University of Southern California (USC) moved the starting point earlier, engineering immature immune progenitor cells to continuously generate cancer-fighting descendants in mice, offering another approach to replenishing the cellular forces used in cell therapy.

The study was published online in *Cell* on June 19, 2026, and the university issued an announcement the same day; ScienceDaily's October 16 coverage described the same study. The findings encompass cultures of human and mouse cells and mouse disease models, rather than a human treatment trial, and do not yet support claims of an “unlimited supply” of cancer-fighting cells in patients.

The team started with granulocyte–monocyte progenitors (GMPs). These cells can generate immune cells such as macrophages, which can enter tumors, engulf targets, and help coordinate immune responses. Once mature, however, macrophages are difficult to expand in large numbers, genetically engineer, and cryopreserve. Expanding and engineering progenitor cells first, then allowing them to generate cells that carry out these tasks, could change the manufacturing process.

Using defined culture conditions, the researchers delayed premature GMP maturation, allowing cells derived from humans and mice to proliferate over the long term while retaining progenitor characteristics and the ability to generate myeloid immune cells. The paper also identified myeloperoxidase as a participant in regulating their proliferation. According to the university's announcement, a collaborating laboratory at Stanford University separately reproduced the results for long-term maintenance and genetic engineering, supporting the method's reproducibility.

Next, the team equipped GMPs with chimeric antigen receptors (CARs), enabling their descendants to recognize specific cancer cell markers. After transfer into mice, these progenitors engrafted in hematopoietic niches such as the bone marrow and generated donor-derived immune cells, including macrophages that entered tumors. In experimental models, CAR-engineered GMPs suppressed the progression of CD19-positive leukemia and HER2-positive solid tumors.

The researchers also incorporated the Fc region of immunoglobulin G into the CAR design to recruit the host's own phagocytes and promote T-cell activation. These immune effects were observed even when the donor and recipient had mismatched major histocompatibility complexes, and the approach improved efficacy in allogeneic transplantation cancer models with intact immune systems. This provides a research direction for cell products manufactured in advance for use in different patients, but is not sufficient to establish that matching or rejection issues can be avoided in humans.

Moving from an expandable cell source to a usable therapy still depends on whether the cells' persistence, differentiation, and immune activity can be safely controlled in the body, and whether tumor suppression in animals can translate into benefits for patients. The study did not establish efficacy in humans or a permanent capacity for replenishment. Related patents have been licensed to Myelogene, and several authors are also company co-founders. These commercial relationships were disclosed in the paper, and further independent validation and clinical evidence are still needed.

References

  1. ScienceDaily Top Health
  2. USC Stem Cell, Keck School of Medicine of USC
  3. PubMed / Cell